The best hair loss treatment for female patients depends on accurate diagnosis, as different causes require entirely different approaches. Hair loss affects a significant proportion of women across all age groups, from hormonal changes and nutritional deficiencies to autoimmune conditions and genetic predisposition. Whether you are experiencing gradual thinning across the crown, sudden diffuse shedding, or patchy loss, effective, evidence-based options are available in the UK. This article outlines the most common causes, how hair loss is diagnosed on the NHS, clinically approved treatments, and when to seek specialist advice.

Common Causes of Hair Loss in Women

Androgenetic alopecia is the most common cause of female hair loss, followed by telogen effluvium, hormonal conditions such as PCOS and thyroid dysfunction, and autoimmune alopecia areata.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss in women is more common than many people realise, affecting a significant proportion of women at some point in their lives, with prevalence increasing with age. Understanding the underlying cause is essential before considering any treatment, as different conditions require very different approaches.

The most prevalent cause is androgenetic alopecia (female-pattern hair loss), a genetically influenced condition characterised by gradual thinning across the crown and top of the scalp, while the frontal hairline is usually preserved. Hormonal changes play a role — oestrogen may help maintain hair in its growth (anagen) phase, though the evidence for progesterone is less clear. Fluctuations during the following can trigger or accelerate hair shedding:

• Pregnancy and postpartum recovery

• Perimenopause and menopause

• Polycystic ovary syndrome (PCOS)

• Thyroid dysfunction (both hypothyroidism and hyperthyroidism)

Telogen effluvium is another common cause, where a physiological stressor — such as significant illness, surgery, rapid weight loss, or nutritional deficiency — pushes a large proportion of hairs into the resting (telogen) phase simultaneously, resulting in diffuse shedding typically two to three months after the triggering event. This form is usually temporary.

Less commonly, alopecia areata — an autoimmune condition — causes patchy hair loss and can affect women of any age. Scarring alopecias, such as lichen planopilaris, are rarer but cause permanent follicle destruction if untreated.

Nutritional deficiencies, particularly iron deficiency, are important to exclude before initiating treatment. Testing for vitamin D and zinc deficiency may be appropriate where there are specific risk factors or dietary concerns, though the evidence linking these to hair loss is mixed and deficiency should not be assumed.

How Hair Loss Is Diagnosed in the UK

Diagnosis begins with a GP consultation including FBC, serum ferritin, and thyroid function tests; referral to a consultant dermatologist is recommended for unexplained, rapid, or scarring hair loss.

Accurate diagnosis is the cornerstone of effective management. In the UK, the diagnostic process typically begins with a GP consultation, during which a thorough medical history and physical examination are conducted. The pattern, distribution, and duration of hair loss, alongside any associated symptoms such as scalp itching, scaling, or systemic features, help guide the differential diagnosis.

First-line blood tests commonly include:

• Full blood count (FBC) — to identify anaemia

• Serum ferritin — a sensitive marker of iron stores

• Thyroid function tests (TFTs) — to exclude hypothyroidism or hyperthyroidism

Additional investigations are guided by clinical features rather than performed routinely. A hormone profile (including androgens, LH, FSH, and prolactin) is appropriate where there are features suggesting hyperandrogenism, menstrual disturbance, or possible PCOS. Vitamin D and zinc levels may be checked where dietary restriction or specific risk factors are present, but are not standard first-line tests for hair loss.

A trichoscopy (dermoscopy of the scalp) may be performed by a dermatologist to assess follicular miniaturisation, a hallmark of androgenetic alopecia, or to identify features of inflammatory or scarring conditions. In some cases, a scalp biopsy is required to confirm a diagnosis, particularly when scarring alopecia is suspected.

NHS pathways recommend that women with unexplained or rapidly progressive hair loss, signs of a scarring alopecia (such as scalp pain, erythema, scaling, or pustules), or features suggesting an underlying systemic condition are referred to a consultant dermatologist. Early and accurate diagnosis not only guides treatment selection but also prevents unnecessary delay in conditions where prompt intervention can preserve follicular function and limit permanent loss.

It is worth noting that trichologists are not medically regulated practitioners and are not part of standard NHS referral pathways. If you choose to consult a trichologist privately, ensure they hold membership of a recognised body such as the Institute of Trichologists or the Trichological Society, and be aware that they cannot diagnose systemic disease or prescribe medication.

NHS and Clinically Approved Treatments for Female Hair Loss

Topical minoxidil is the primary licensed treatment for female-pattern hair loss; anti-androgens and JAK inhibitors are available under specialist supervision for specific diagnoses.

Treatment options for female hair loss vary depending on the underlying cause, and not all treatments are available on the NHS — some are only accessible privately. Several clinically approved and evidence-based options exist.

Minoxidil is a licensed treatment for female-pattern hair loss in the UK. Two formulations are available:

• 2% topical solution — licensed for women, applied twice daily

• 5% cutaneous foam — licensed for women, applied once daily

Minoxidil works by prolonging the anagen (growth) phase of the hair cycle and increasing follicular size. Results are usually visible after three to six months of continuous use. An initial increase in shedding during the first few weeks is common and does not indicate treatment failure. Hair loss resumes if treatment is discontinued. Common side effects include application-site irritation and unwanted facial hair (hypertrichosis). Minoxidil should not be used during pregnancy or breastfeeding. Patients should report any suspected side effects via the MHRA Yellow Card scheme.

Experiencing these side effects? Our pharmacists can help you navigate them →

For women with PCOS or hyperandrogenism, anti-androgen medications may be prescribed off-label under specialist supervision:

• Spironolactone — used off-label for female-pattern hair loss; requires monitoring of blood pressure and electrolytes (U&Es), and effective contraception is essential due to the risk of feminisation of a male foetus

• Cyproterone acetate — often combined with an oral contraceptive; the MHRA has issued safety restrictions due to a dose-dependent risk of meningioma and a risk of venous thromboembolism (VTE), particularly with co-cyprindiol; it should only be initiated by a specialist following appropriate counselling

In cases of alopecia areata, treatments may include:

• Topical, intralesional, or systemic corticosteroids

• Topical immunotherapy (diphencyprone) — available in specialist centres

• JAK inhibitors — the MHRA has granted marketing authorisations for baricitinib (Olumiant) and ritlecitinib (Litfulo) for severe alopecia areata in adults. Patients and clinicians should refer to current NICE Technology Appraisals to confirm NHS commissioning status and eligibility criteria. These agents carry important class warnings including risk of serious infections, venous thromboembolism, major adverse cardiovascular events (MACE), and malignancy; specialist initiation and monitoring are required

For telogen effluvium secondary to nutritional deficiency, correcting the underlying deficiency — for example, with iron supplementation — is the primary treatment. There is no licensed pharmacological therapy specifically for this condition.

Comparing Treatment Options: What the Evidence Says

Minoxidil has the strongest evidence base for female-pattern hair loss; no single treatment is universally best, as the optimal choice depends on diagnosis, severity, and individual medical history.

When evaluating the best hair loss treatment for female patients, it is important to weigh the quality of evidence, tolerability, and suitability for the individual's specific diagnosis and circumstances.

Minoxidil has the strongest evidence base for female-pattern hair loss. Multiple randomised controlled trials have demonstrated statistically significant improvements in hair count and patient-reported outcomes with both the 2% solution and 5% foam. The 5% concentration has shown superior efficacy in some studies, though it carries a slightly higher risk of unwanted facial hair growth.

A low-dose oral minoxidil formulation (typically 0.25–1 mg daily) is increasingly used off-label and has shown promising results in observational studies; however, it is not licensed for hair loss in the UK. It should only be initiated by a specialist following a cardiovascular history review, as potential side effects include postural hypotension, tachycardia, fluid retention, and hypertrichosis. Rare but serious effects include pericardial effusion. Suspected adverse effects should be reported via the MHRA Yellow Card scheme.

Anti-androgens such as spironolactone have a growing evidence base, particularly in women with elevated androgens, though large-scale randomised trials remain limited. Effective contraception is mandatory during treatment, and periodic monitoring of blood pressure and electrolytes (U&Es) is required.

For alopecia areata, the evidence for JAK inhibitors is compelling — both baricitinib and ritlecitinib demonstrated significant hair regrowth in phase III trials — but long-term safety data are still accumulating. These agents are currently reserved for severe or refractory cases and are subject to NHS commissioning decisions; patients should discuss eligibility with their dermatologist.

Platelet-rich plasma (PRP) therapy and low-level laser therapy (LLLT) are increasingly offered in private clinics. While some studies suggest modest benefit, the evidence remains heterogeneous and neither is routinely commissioned by the NHS. Patients considering these options privately should seek treatment from regulated, qualified practitioners.

In summary, no single treatment is universally best — the most appropriate option depends on diagnosis, severity, patient preference, and medical history.

When to See a GP or Specialist About Hair Loss

See your GP promptly if you notice sudden shedding, patchy loss, scalp inflammation, signs of virilisation, or hair loss significantly affecting your mental wellbeing.

Many women delay seeking medical advice about hair loss, often attributing it to stress or ageing. However, early assessment is important, particularly when hair loss may signal an underlying medical condition or when prompt treatment could prevent permanent follicle damage.

Contact your GP if you notice:

• Sudden or rapid hair shedding over a short period

• Patchy or asymmetric hair loss

• Scalp redness, scaling, itching, pain, or pustules (which may suggest a scarring alopecia requiring urgent assessment)

• Signs of virilisation, such as deepening of the voice or increased facial hair, alongside hair loss

• Hair loss accompanied by fatigue, weight changes, or irregular periods

• Significant thinning that is affecting your quality of life or mental wellbeing

• Hair loss following a new medication (drug-induced alopecia is a recognised side effect of several agents, including anticoagulants, retinoids, and some antidepressants)

Your GP can initiate baseline investigations and, where appropriate, refer you to an NHS consultant dermatologist. Waiting times on the NHS can vary; if you are concerned about delays, a private consultation with a consultant dermatologist is a reasonable option. If you choose to see a trichologist privately, be aware that they are not medically regulated and cannot diagnose systemic disease or prescribe medication — ensure they hold membership of a recognised professional body.

Hair loss can have a significant psychological impact. If you are experiencing anxiety, low mood, or reduced self-esteem as a result of hair loss, do not hesitate to raise this with your GP. Psychological support, including referral to NHS Talking Therapies for anxiety and depression, may be appropriate alongside any medical treatment.

Lifestyle and Supportive Measures Alongside Treatment

Ensuring adequate iron and protein intake, avoiding crash dieting, practising gentle scalp care, and managing stress can complement medical treatment and reduce additional shedding.

Whilst medical treatments form the backbone of managing female hair loss, lifestyle and supportive measures play a meaningful complementary role. These approaches will not reverse established androgenetic alopecia on their own, but they can help optimise the scalp environment, reduce additional shedding, and support overall hair health.

Nutritional optimisation is particularly important. Ensuring adequate intake of:

• Iron — found in red meat, legumes, and leafy greens; supplementation should only be used where a deficiency has been confirmed by blood tests

• Protein — hair is composed primarily of keratin, making adequate dietary protein essential

• Biotin, zinc, and vitamin D — supplementation is only beneficial if a deficiency is confirmed; if you are taking biotin supplements, inform your clinician before blood tests, as biotin can interfere with certain laboratory assays (including thyroid function tests and troponin measurements), potentially causing misleading results

...can help reduce diet-related shedding. Crash dieting and very low-calorie diets are a well-recognised trigger for telogen effluvium and should be avoided.

Scalp care also matters. Gentle shampooing with a mild, pH-balanced shampoo, avoiding excessive heat styling, and minimising chemical treatments can reduce mechanical and thermal damage to fragile hair shafts. Tight hairstyles such as high ponytails or braids can cause traction alopecia, a preventable form of hair loss that, if prolonged, may lead to permanent damage.

Stress management is another important consideration. Chronic psychological stress has been associated with disruption of the hair cycle, though the relationship is complex and not fully established as directly causal. Practices such as regular physical activity, adequate sleep, and mindfulness-based techniques may be beneficial.

Finally, camouflage and psychological support should not be overlooked. Products such as volumising sprays, scalp concealers, and hair fibres can provide immediate cosmetic relief while treatments take effect. Organisations such as Alopecia UK offer peer support, resources, and community for women navigating hair loss at any stage.

Frequently Asked Questions